Sponsor
Theodore Paul Budd
Senator · R-NC
Senator · R-NC
The bill strengthens drug-supply safety, transparency, and resilience—especially against tainted products and forced-labor risks—but does so at the cost of higher compliance and production costs, greater regulatory burden, and an elevated risk of transitional shortages and trade friction.
Patients and hospitals: stronger blocking, inspection, and enforcement authorities plus tighter inspection timing reduce the likelihood that counterfeit, adulterated, or unapproved drugs and contaminated APIs reach U.S. patients.
Hospitals, state governments, and Congress: quarterly facility- and shipment-level reporting plus annual public reports and confidential analyses give regulators and health systems much better visibility into supply-chain vulnerabilities so problems can be identified and addressed sooner.
Patients, hospitals, and taxpayers: incentives and requirements aimed at reducing reliance on single-country sources (notably China) and encouraging diversification or reshoring should strengthen long-term resilience of U.S. drug supplies and lower systemic risk of foreign-sourced disruptions.
Patients, hospitals, and taxpayers: tighter import controls, increased inspections, reporting burdens, destruction obligations, and reshoring incentives are likely to raise drug production and distribution costs and therefore drug prices and public expenditures.
Patients and hospitals: delisting foreign suppliers, stricter inspections, and transitional disruptions could cause or worsen shortages of drugs and APIs, interrupting access to essential medicines.
Importers, wholesalers, and small businesses: quarterly reporting, extended record retention, new prohibited acts and criminal exposure, and costs (including mandated destruction within 90 days) create significant administrative, compliance, and legal burdens.
Based on analysis of 6 sections of legislative text.
Tightens import controls and inspection/reporting rules for APIs and drug components, adds grounds to refuse/destroy imports tied to forced labor or sanctions, and requires quarterly facility-level supply-chain reporting.
Official title: Direct the Food and Drug Administration to prevent the importation of counterfeit, unapproved, misbranded, or adulterated drugs from the People's Republic of China or other foreign countries, to establish enhanced safeguards for imported drug products, and for other purposes.
Introduced July 21, 2026 by Theodore Paul Budd · Last progress July 21, 2026
Strengthens federal controls over imported drugs, active pharmaceutical ingredients (APIs), and key starting materials—with special focus on products originating in the People’s Republic of China or other designated foreign countries of concern. It requires faster, more detailed supply-chain reporting from drug and device registrants, expands grounds to refuse or destroy imports linked to forced labor or sanctions violations, and directs the Secretary of HHS to use FDA authorities to block counterfeit, unapproved, misbranded, or adulterated drugs and materials. The bill creates new inspection, reporting, and enforcement timelines (including quarterly API/source reporting and deadlines for proposed and final regulations), mandates regular reports to Congress analyzing U.S. supply vulnerabilities, and adds civil and criminal enforcement tools and misbranding/adulteration grounds tied to foreign sourcing and forced labor.